UAB Hematology Review 2021
2021 Updates on 2L CML and Beyond: TKIs (Imatinib, Dasatinib/Nilotinib/Bosutinib Continuation, Ponatinib), Omacetaxine, Asciminib, HQP1351
By
UAB Hematology Review 2021
FEATURING
Omer Jamy
By
UAB Hematology Review 2021
FEATURING
Omer Jamy
Login to view comments.
Click here to Login